Compounds > quinazolines

Page last updated: 2024-08-21

quinazolines and Paronychia

quinazolines has been researched along with Paronychia in 18 studies

Research

Studies (18)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (38.89)	29.6817
2010's	11 (61.11)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hirashima, T; Iwata, K; Masuhiro, K; Morishita, N; Morita, S; Nasu, S; Okamoto, N; Ryota, N; Shiroyama, T; Suzuki, H; Takata, SO; Tanaka, A; Ueda, Y	1
Fujita, S; Fukushima, S; Imamichi, F; Irie, K; Katakami, N; Masago, K; Okada, Y; Yatabe, Y	1
Chu, CY; Hauschild, A; Lacouture, ME; O'Brien, D; Schadendorf, D; Stammberger, U; Uttenreuther-Fischer, M	1
Kishi, A; Kiyohara, Y; Yamazaki, N	1
Arriola, E; Artal, A; Cobo, M; Esteban, E; García-Campelo, R; García-Muret, MP; Reguart, N; Rodríguez, MC	1
Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW	1
Belyayeva, Y; Gkouvi, A; Gregoriou, S; Katsambas, A; Larios, G; Rigopoulos, D	1
Alexandrescu, DT; Dasanu, CA; Kauffman, CL	1
Dirschka, T; Hauschild, A; Kroth, J; Wollenberg, A	1
Frankel, C; Palmieri, FM	1
Becker, A; Postmus, PE; Smit, EF; van Wijk, A	1
Beinert, T; Binder, D; Buckendahl, AC; Hübner, RH; Schlattmann, P; Suttorp, N; Temmesfeld-Wollbrück, B	1
Byun, SY; Choi, JW; Hong, JS; Huh, CH; Kwon, SH; Na, JI; Park, KC; Youn, SW	1
Nakamura, M; Nakano, J	1
Dainichi, T; Furue, M; Noda, K; Tanaka, M; Tsuruta, N	1
Choi, JH; Kim, SW; Koh, JK; Lee, HW; Lee, MW; Moon, KC; Seo, CW; Yang, HJ	1
Chang, GC; Chen, KC; Lin, YC; Wang, RC; Yang, TY; Yin, MC	1
Koldenhof, JJ; Sigurdsson, V; Tjin-A-ton, ML; van Montfrans, C; Voest, EE; Witteveen, PO	1

Reviews

6 review(s) available for quinazolines and Paronychia

Article	Year
Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert review of anticancer therapy, 2013, Volume: 13, Issue:6 Topics: Administration, Oral; Afatinib; Alopecia; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Exanthema; Humans; Paronychia; Protein Kinase Inhibitors; Pruritus; Quinazolines; Receptor, ErbB-2	2013
Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:3 Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Patient Education as Topic; Pruritus; Quinazolines	2013
Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel. Future oncology (London, England), 2015, Volume: 11, Issue:2 Topics: Afatinib; Antineoplastic Agents; Diarrhea; Disease Management; Exanthema; Humans; Mucositis; Neoplasms; Paronychia; Practice Guidelines as Topic; Quinazolines; Spain; Stomatitis	2015
Acute paronychia caused by lapatinib therapy. Clinical and experimental dermatology, 2009, Volume: 34, Issue:1 Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Paronychia; Quinazolines	2009
[Cutaneous side effects of EGFR inhibitors--appearance and management]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:4 Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines	2010
Lapatinib side-effect management. Clinical journal of oncology nursing, 2010, Volume: 14, Issue:2 Topics: Antineoplastic Agents; Diarrhea; Humans; Lapatinib; Paronychia; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases	2010

Other Studies

12 other study(ies) available for quinazolines and Paronychia

Article	Year
Skin Rash Can Be a Useful Marker for Afatinib Efficacy. Anticancer research, 2018, Volume: 38, Issue:3 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Stomatitis; Treatment Outcome	2018
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Oncology, 2018, Volume: 95, Issue:4 Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines	2018
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer. JAMA dermatology, 2016, Volume: 152, Issue:3 Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies	2016
Persistent hair growth during treatment with the EGFR inhibitor erlotinib. Dermatology online journal, 2009, Mar-15, Volume: 15, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Hair; Hair Color; Humans; Hypertrichosis; Lung Neoplasms; Neoplasm Proteins; Paronychia; Protein Kinase Inhibitors; Quinazolines; Remission Induction	2009
Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:9 Topics: Adenocarcinoma; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Folliculitis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome	2010
Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction	2012
Gefitinib-induced paronychia: response to autologous platelet-rich plasma. Archives of dermatology, 2012, Volume: 148, Issue:12 Topics: Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Paronychia; Platelet-Rich Plasma; Quinazolines	2012
Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor. The Journal of dermatology, 2003, Volume: 30, Issue:3 Topics: Aged; Aged, 80 and over; Biopsy, Needle; Enzyme Inhibitors; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Paronychia; Quinazolines; Risk Assessment; Severity of Illness Index	2003
Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dermatology (Basel, Switzerland), 2003, Volume: 207, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Nail Diseases; Paronychia; Quinazolines; Risk Assessment; Severity of Illness Index	2003
Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta dermato-venereologica, 2004, Volume: 84, Issue:1 Topics: Acneiform Eruptions; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Quinazolines; Retrospective Studies; Signal Transduction; Skin; Urticaria	2004
Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Nov-15, Volume: 22, Issue:22 Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Hyperpigmentation; Lung Neoplasms; Middle Aged; Paronychia; Protein-Tyrosine Kinases; Quinazolines	2004
[Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors]. Nederlands tijdschrift voor geneeskunde, 2007, Apr-28, Volume: 151, Issue:17 Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma; Cetuximab; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines	2007